Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts
NCT ID: NCT01365273
Last Updated: 2014-02-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
43 participants
INTERVENTIONAL
2011-02-28
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The primary objective is to compare pain at the time of dressing change for the use of Mepitel One versus bridal veil together with staples on deep partial or full thickness burns requiring skin grafts.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns
NCT01636362
A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.
NCT02210208
Microsurfaced Grafts in Deep Burn Wounds
NCT04589442
CONTINUED ACCESS PROTOCOL: Demonstration of the Safety and Effectiveness of ReCell® Combined With Meshed Skin Graft for Reduction of Donor Area in the Treatment of Acute Burn Injuries
NCT02994654
An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.
NCT01734317
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Graft take can be optimized with appropriate medical management. Use of non-adherent dressings to protect the graft is customary. Various types of netting-style are used, such as Bridal veil, a sterile product which is fixed over the graft with staples.
Silicone net dressings have also been used successfully to prevent lifting and adherence of skin grafts to the dressings, prevent pain and promote healing. Mepitel One is a sterile, transparent, and flexible wound contact layer consisting of perforated polyurethane film coated with Safetac soft silicone adhesive on one side. Mepitel One is available in various sizes and can be left in place for several days depending on the wound/skin condition.
Evaluation of burns will be performed at Baseline. Skin graft assessment will be performed at Day 7 and Day 14. End of study will be considered the time that graft is considered to have \>95% take.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bridal Veil together with staples
Standard of care. Bridal Veil is fixed over the graft with staples.
No interventions assigned to this group
Mepitel One
Device, dressing
Mepitel One
Dressing
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mepitel One
Dressing
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. At least 1%-10% TBSA is available for grafting that can be considered for study site selection (must have intact, healthy peri-wound area around entire portion of this burned site)
3. Both genders with age ≥18 years but \< 70 years
4. Signed informed consent
Exclusion Criteria
2. Subjects who are on mechanical ventilation
3. Subjects with dermatologic skin conditions or necrotizing disorders
4. Diagnosed underlying disease(s) (HIV/AIDS, cancer and severe anaemia)judged by the investigator to be a potential interference in the treatment
5. Subjects treated with systemic glucocorticosteroids, except subjects taking occasional doses or doses less than 10 mg prednisolon/day or equivalent
6. Use of immunosuppressive agents, radiation or chemotherapy within the past 30 days
7. Known allergy/hypersensitivity to any of the components of the investigational products
8. Subjects with physical and/or mental conditions that are not expected to comply with the investigation
9. Participation in other clinical investigation(s) within 1 month prior to start of the investigation
10. Previously randomised to this investigation
11. Pregnancy
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Molnlycke Health Care AB
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mary Lou Patton, MD
Role: PRINCIPAL_INVESTIGATOR
Nathan Speare Regional Burn Treatment Ctr. Croer Chester Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Foundation for Education & Research, Inc
Tampa, Florida, United States
Joseph M. Still Research Foundation, Inc.
Augusta, Georgia, United States
5028 Delp Bldg, Mail stop 1011
Kansas City, Kansas, United States
Natham Speare Regional Burn Treatment Ctr., Crozer Chester Medical Center
Upland, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MPTO 04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.